

## Ansuvimab

Cat. No.:	HY-P99337
CAS No.:	2375952-29-5
Target:	Filovirus
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells <sup>[1]</sup> .
IC <sub>50</sub> & Target	Zaire ebolavirus <sup>[1]</sup>
In Vitro	Ansuvimab blocks binding between the Ebola virus glycoprotein (GP) and the Niemann-Pick C1 receptor by binding to the LEIKKPDGS epitope located in the receptor binding site of the GP1 subunit of GP <sup>[1]</sup> . Ansuvimab mediates antibody-dependent cellular cytotoxicity (ADCC) against GP-transfected target cells, with maximal activity at the concentration of 0.03 µg/mL <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Ansuvimab results in all macaques surviving after exposure to a lethal dose of Ebola virus in on day 0 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Lee A, et, al. Ansuvimab: First Approval. *Drugs*. 2021 Apr;81(5):595-598.

[2]. Corti D, et, al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. *Science*. 2016 Mar 18;351(6279):1339-42.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA